Mayne Pharma Group Stock | MYX.AX | AU000000MYX0 | A1C821

Date	Mayne Pharma Group Price
11/29/2024	5.13 undefined
11/28/2024	4.78 undefined
11/27/2024	4.95 undefined
11/26/2024	4.77 undefined
11/25/2024	4.85 undefined
11/22/2024	4.48 undefined
11/21/2024	4.26 undefined
11/20/2024	4.45 undefined
11/19/2024	4.65 undefined
11/18/2024	4.69 undefined
11/15/2024	4.89 undefined
11/14/2024	4.90 undefined
11/13/2024	4.92 undefined
11/12/2024	5.29 undefined
11/11/2024	5.20 undefined
11/8/2024	5.10 undefined
11/7/2024	4.43 undefined
11/6/2024	4.42 undefined
11/5/2024	4.25 undefined
11/4/2024	4.38 undefined

Date	Mayne Pharma Group Revenue	Mayne Pharma Group EBIT	Mayne Pharma Group Net Income
2027e	562.27 M undefined	28.66 M undefined	19.08 M undefined
2026e	480.91 M undefined	-1.91 M undefined	-4.55 M undefined
2025e	438.85 M undefined	-22.22 M undefined	-19.08 M undefined
2024	395.47 M undefined	-155.3 M undefined	-174.23 M undefined
2023	190.31 M undefined	-165.45 M undefined	117.25 M undefined
2022	157.61 M undefined	-55.87 M undefined	-281.29 M undefined
2021	401.47 M undefined	20.55 M undefined	-208.42 M undefined
2020	457.77 M undefined	4.86 M undefined	-92.79 M undefined
2019	526.22 M undefined	52.46 M undefined	-279.2 M undefined
2018	530.43 M undefined	62.72 M undefined	-133.98 M undefined
2017	572.6 M undefined	129.82 M undefined	88.57 M undefined
2016	267.28 M undefined	58.8 M undefined	37.36 M undefined
2015	141.42 M undefined	19.4 M undefined	7.76 M undefined
2014	143.3 M undefined	29.8 M undefined	21.3 M undefined
2013	84.1 M undefined	11.2 M undefined	-2.8 M undefined
2012	52.5 M undefined	6 M undefined	6.2 M undefined
2011	50.1 M undefined	2.4 M undefined	1.7 M undefined
2010	36.7 M undefined	2 M undefined	3.3 M undefined
2009	400,000 undefined	-4.7 M undefined	-3.8 M undefined
2008	800,000 undefined	-3.4 M undefined	-3.5 M undefined
2007	100,000 undefined	-1.8 M undefined	-1.8 M undefined
2006	0 undefined	0 undefined	0 undefined

	Revenue	EBIT	Net Income
2006	0 AUD	0 AUD	0 AUD
2007	100,000 AUD	-1.8 M AUD	-1.8 M AUD
2008	800,000 AUD	-3.4 M AUD	-3.5 M AUD
2009	400,000 AUD	-4.7 M AUD	-3.8 M AUD
2010	36.7 M AUD	2 M AUD	3.3 M AUD
2011	50.1 M AUD	2.4 M AUD	1.7 M AUD
2012	52.5 M AUD	6 M AUD	6.2 M AUD
2013	84.1 M AUD	11.2 M AUD	-2.8 M AUD
2014	143.3 M AUD	29.8 M AUD	21.3 M AUD
2015	141.42 M AUD	19.4 M AUD	7.76 M AUD
2016	267.28 M AUD	58.8 M AUD	37.36 M AUD
2017	572.6 M AUD	129.82 M AUD	88.57 M AUD
2018	530.43 M AUD	62.72 M AUD	-133.98 M AUD
2019	526.22 M AUD	52.46 M AUD	-279.2 M AUD
2020	457.77 M AUD	4.86 M AUD	-92.79 M AUD
2021	401.47 M AUD	20.55 M AUD	-208.42 M AUD
2022	157.61 M AUD	-55.87 M AUD	-281.29 M AUD
2023	190.31 M AUD	-165.45 M AUD	117.25 M AUD
2024	395.47 M AUD	-155.3 M AUD	-174.23 M AUD
2025e	438.85 M AUD	-22.22 M AUD	-19.08 M AUD
2026e	480.91 M AUD	-1.91 M AUD	-4.55 M AUD
2027e	562.27 M AUD	28.66 M AUD	19.08 M AUD

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0	15.3	11.5	7.9	19.7	5.8	11.6	18.9	14.8	59.2	47.48	63.03	87.31	89	137.79	97.98	96.67	220.14	149.28
0	0.1	0	0	5.1	5	3	23.9	28.8	62.51	91.54	223.56	251.67	250.98	191.99	173.47	259.04	177.4	176.47
0	0	0	0	0.9	1.3	0.8	2.3	2	5.1	7.97	10.24	23.25	6.12	41.25	17.51	23.3	32.12	31.21
0	0	0	0	6.5	6.4	7.2	13.6	17.2	22.44	38.94	106.39	82.16	100.35	94	102.51	108.91	82.7	74.63
0	0.1	0.1	0	0.3	0.3	0.6	3.1	3	7.56	891.11	18.89	36.38	25.49	25.93	25.06	23.7	41.27	29.01
0	0.02	0.01	0.01	0.03	0.02	0.02	0.06	0.07	0.16	1.08	0.42	0.48	0.47	0.49	0.42	0.51	0.55	0.46
0	0.1	0	0	21	21.5	22.2	55	53.4	59.6	84.45	189.27	230.05	236.03	238.24	221.6	225.86	51.48	53.33
0	0	0	0	0	0	0	0	4.1	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12.59	0	0	0
0	0	0	0	0.01	0.01	0	0.07	0.09	0.24	0.27	1.18	1.03	0.78	0.94	0.62	0.41	0.62	0.57
0	0	0	0	0.4	0.4	0.4	47.2	47.5	58.44	60.12	58.22	20.62	21.73	22.17	20.35	22.13	0	0
0	0	0	0	3.3	5.2	4.3	1	1.3	9.57	31.8	61.2	65.16	130.13	133.7	176.32	122.94	24.98	60.68
0	0	0	0	0.04	0.03	0.03	0.17	0.2	0.37	0.45	1.49	1.35	1.16	1.33	1.05	0.78	0.69	0.68
0	0.02	0.01	0.01	0.07	0.05	0.05	0.23	0.27	0.53	1.53	1.91	1.83	1.64	1.83	1.46	1.29	1.25	1.14

0	0.02	0.02	0.02	0.03	0.03	0.03	0.12	0.14	0.26	0.26	1.13	1.13	1.14	1.24	1.24	1.24	1.23	1.22
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-1.4	-4.4	-8.2	-4.1	-7.7	-1.4	-4.3	18.3	27.41	70.66	160.97	40.62	-232.35	-318.2	-518.89	-794.57	-716.96	-888.56
0	0	0	0	0	0	0	6.8	3.4	27.63	29.93	12.47	54.09	99.51	117.17	48.71	101.91	117.62	118.53
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.01	0.01	0.01	0.03	0.02	0.03	0.12	0.16	0.31	0.36	1.3	1.23	1.01	1.04	0.77	0.55	0.63	0.45
0	0.2	0.1	0.1	2.2	2.1	2.9	6.8	7.1	51.57	64.05	66.59	63.89	50.44	29.84	42.36	63.57	32.03	20.87
0	0	0	0	0	0	0	0	6.6	6.52	49.15	72.73	79.25	68.44	70.49	63.78	113.19	195.87	179.85
0	0.8	0.1	0.2	13.4	10.5	9.4	27.8	14.3	36.98	910.63	40.57	37.53	41.56	74.08	62.34	44.55	68.64	109.39
0	0	0	0	0	0	0	0	0	0	0	0	0	36.62	41.23	42.16	63.11	10.81	0
0	0	0	0	7.6	2.3	0	7.5	2.4	0	0.5	13.12	0.06	14.26	3.61	11.89	344.88	3.62	3.82
0	0	0	0	0.02	0.01	0.01	0.04	0.03	0.1	1.02	0.19	0.18	0.21	0.22	0.22	0.63	0.31	0.31
0	0	0	0	1	0	0	39.2	45.7	62.75	76.33	327.12	374.13	318.5	353.21	292.78	5.67	33.08	35
0	0	0	0	5.5	4.5	3.7	20.6	21.8	41.35	41.64	56.91	34.03	31.36	28.98	13.46	6.03	7.8	7.35
0	0	0	0	15.9	10.1	7.3	10.6	8.7	7.56	7.27	18.57	6.46	61.07	181.42	162.84	108.68	261.16	332.7
0	0	0	0	22.4	14.6	11	70.4	76.2	111.67	125.24	402.6	414.63	410.93	563.61	469.08	120.38	302.04	375.05
0	0	0	0	0.05	0.03	0.02	0.11	0.11	0.21	1.15	0.6	0.6	0.62	0.78	0.69	0.75	0.61	0.69
0	0.02	0.01	0.01	0.07	0.05	0.05	0.23	0.27	0.52	1.51	1.9	1.82	1.63	1.82	1.46	1.3	1.25	1.14

2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-281	117
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	78	70
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	68	69
0	0	0	-22	0	0	-5	-4	-8	-20	10	-15	-27	-30	-22	-32	-38
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	200	-381
0	0	0	0	0	0	-2	-3	-4	-1	-10	-15	-14	-13	0	0	0
0	0	0	0	-2	0	-2	-3	-7	-26	-57	-7	21	-1	10	7	-4
-1	-3	-3	10	4	13	5	25	22	53	-15	121	106	99	58	-7	-42
0	0	0	0	-2	-2	-21	-31	-83	-62	-1,083	-94	-81	-47	-25	-11	-219
0	0	0	-18	-2	-5	-125	-50	-95	-83	-1,097	-118	-91	-55	-49	-28	473
0	0	0	-18	0	-2	-104	-18	-11	-20	-13	-24	-9	-8	-24	-16	693
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	8	-5	-2	40	2	1	13	269	18	-22	4	-28	37	-375
16	0	0	14	1	0	89	18	118	0	892	1	7	0	0	0	-6
0.02	0	0	0.02	-0.01	-0	0.13	0.02	0.12	0.02	1.13	0.02	-0.02	0	-0.04	0.03	-0.43
0	0	0	-1	-6	0	-4	0	-4	3	-32	0	0	0	-11	-9	-4
0	0	0	0	-4	0	0	0	0	0	0	0	0	0	0	0	-45
13	-7	-8	44	-7	18	22	32	86	89	56	184	129	194	30	16	-3
-1.3	-3	-3.6	9.9	2	10.9	-15.4	-6.1	-61.55	-9.72	-1,099.52	27.16	24.69	52.66	33.77	-19.06	-262.3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Mayne Pharma Group Gross margin	Mayne Pharma Group Profit margin	Mayne Pharma Group EBIT margin	Mayne Pharma Group Profit margin
2027e	57.11 %	5.1 %	3.39 %
2026e	57.11 %	-0.4 %	-0.95 %
2025e	57.11 %	-5.06 %	-4.35 %
2024	57.11 %	-39.27 %	-44.06 %
2023	47.51 %	-86.94 %	61.61 %
2022	47.74 %	-35.45 %	-178.47 %
2021	45.5 %	5.12 %	-51.92 %
2020	46.38 %	1.06 %	-20.27 %
2019	60.13 %	9.97 %	-53.06 %
2018	53.61 %	11.82 %	-25.26 %
2017	56.82 %	22.67 %	15.47 %
2016	63.79 %	22 %	13.98 %
2015	56.56 %	13.71 %	5.49 %
2014	52.41 %	20.8 %	14.86 %
2013	47.21 %	13.32 %	-3.33 %
2012	44.19 %	11.43 %	11.81 %
2011	46.31 %	4.79 %	3.39 %
2010	47.96 %	5.45 %	8.99 %
2009	100 %	-1,175 %	-950 %
2008	57.11 %	-425 %	-437.5 %
2007	57.11 %	-1,800 %	-1,800 %
2006	57.11 %	0 %	0 %

	Gross margin	EBIT margin	Profit margin
2006	57.11 %	0 %	0 %
2007	57.11 %	-1,800 %	-1,800 %
2008	57.11 %	-425 %	-437.5 %
2009	100 %	-1,175 %	-950 %
2010	47.96 %	5.45 %	8.99 %
2011	46.31 %	4.79 %	3.39 %
2012	44.19 %	11.43 %	11.81 %
2013	47.21 %	13.32 %	-3.33 %
2014	52.41 %	20.8 %	14.86 %
2015	56.56 %	13.71 %	5.49 %
2016	63.79 %	22 %	13.98 %
2017	56.82 %	22.67 %	15.47 %
2018	53.61 %	11.82 %	-25.26 %
2019	60.13 %	9.97 %	-53.06 %
2020	46.38 %	1.06 %	-20.27 %
2021	45.5 %	5.12 %	-51.92 %
2022	47.74 %	-35.45 %	-178.47 %
2023	47.51 %	-86.94 %	61.61 %
2024	57.11 %	-39.27 %	-44.06 %
2025e	57.11 %	-5.06 %	-4.35 %
2026e	57.11 %	-0.4 %	-0.95 %
2027e	57.11 %	5.1 %	3.39 %

Date	Mayne Pharma Group Sales per Share	Mayne Pharma Group EBIT per share	Mayne Pharma Group Earnings per Share
2027e	6.61 undefined	0 undefined	0.22 undefined
2026e	5.65 undefined	0 undefined	-0.05 undefined
2025e	5.16 undefined	0 undefined	-0.22 undefined
2024	4.97 undefined	-1.95 undefined	-2.19 undefined
2023	2.32 undefined	-2.01 undefined	1.43 undefined
2022	1.92 undefined	-0.68 undefined	-3.42 undefined
2021	5.11 undefined	0.26 undefined	-2.65 undefined
2020	5.99 undefined	0.06 undefined	-1.21 undefined
2019	7.13 undefined	0.71 undefined	-3.79 undefined
2018	7.25 undefined	0.86 undefined	-1.83 undefined
2017	7.84 undefined	1.78 undefined	1.21 undefined
2016	0.31 undefined	0.07 undefined	0.04 undefined
2015	0.2 undefined	0.03 undefined	0.01 undefined
2014	0.22 undefined	0.05 undefined	0.03 undefined
2013	0.19 undefined	0.03 undefined	-0.01 undefined
2012	0.24 undefined	0.03 undefined	0.03 undefined
2011	0.23 undefined	0.01 undefined	0.01 undefined
2010	0.21 undefined	0.01 undefined	0.02 undefined
2009	0 undefined	-0.04 undefined	-0.04 undefined
2008	0.01 undefined	-0.03 undefined	-0.03 undefined
2007	0 undefined	-0.03 undefined	-0.03 undefined
2006	0 undefined	0 undefined	0 undefined

	Sales per Share	EBIT per share	Earnings per Share
2006	0 AUD	0 AUD	0 AUD
2007	0 AUD	-0.03 AUD	-0.03 AUD
2008	0.01 AUD	-0.03 AUD	-0.03 AUD
2009	0 AUD	-0.04 AUD	-0.04 AUD
2010	0.21 AUD	0.01 AUD	0.02 AUD
2011	0.23 AUD	0.01 AUD	0.01 AUD
2012	0.24 AUD	0.03 AUD	0.03 AUD
2013	0.19 AUD	0.03 AUD	-0.01 AUD
2014	0.22 AUD	0.05 AUD	0.03 AUD
2015	0.2 AUD	0.03 AUD	0.01 AUD
2016	0.31 AUD	0.07 AUD	0.04 AUD
2017	7.84 AUD	1.78 AUD	1.21 AUD
2018	7.25 AUD	0.86 AUD	-1.83 AUD
2019	7.13 AUD	0.71 AUD	-3.79 AUD
2020	5.99 AUD	0.06 AUD	-1.21 AUD
2021	5.11 AUD	0.26 AUD	-2.65 AUD
2022	1.92 AUD	-0.68 AUD	-3.42 AUD
2023	2.32 AUD	-2.01 AUD	1.43 AUD
2024	4.97 AUD	-1.95 AUD	-2.19 AUD
2025e	5.16 AUD	0 AUD	-0.22 AUD
2026e	5.65 AUD	0 AUD	-0.05 AUD
2027e	6.61 AUD	0 AUD	0.22 AUD

	Number of stocks
2006	29.4 M Aktien
2007	62 M Aktien
2008	106.8 M Aktien
2009	106.8 M Aktien
2010	178.7 M Aktien
2011	215.1 M Aktien
2012	214.6 M Aktien
2013	443.3 M Aktien
2014	645.6 M Aktien
2015	715.45 M Aktien
2016	858 M Aktien
2017	73.02 M Aktien
2018	73.14 M Aktien
2019	73.75 M Aktien
2020	76.47 M Aktien
2021	78.58 M Aktien
2022	82.3 M Aktien
2023	82.18 M Aktien
2024	79.62 M Aktien
2025e	79.62 M Aktien
2026e	79.62 M Aktien
2027e	79.62 M Aktien

Date	Mayne Pharma Group Dividend
2027e	0.27 undefined
2026e	-0.06 undefined
2025e	-0.27 undefined
2023	0.78 undefined
2011	0.01 undefined
2010	0.02 undefined

	Dividend	Dividend (Estimate)
2006	0 AUD	0 AUD
2007	0 AUD	0 AUD
2008	0 AUD	0 AUD
2009	0 AUD	0 AUD
2010	0.02 AUD	0 AUD
2011	0.01 AUD	0 AUD
2012	0 AUD	0 AUD
2013	0 AUD	0 AUD
2014	0 AUD	0 AUD
2015	0 AUD	0 AUD
2016	0 AUD	0 AUD
2017	0 AUD	0 AUD
2018	0 AUD	0 AUD
2019	0 AUD	0 AUD
2020	0 AUD	0 AUD
2021	0 AUD	0 AUD
2022	0 AUD	0 AUD
2023	0.78 AUD	0 AUD
2024	0 AUD	0 AUD
2025e	0 AUD	-0.27 AUD
2026e	0 AUD	-0.06 AUD
2027e	0 AUD	0.27 AUD

Date	Mayne Pharma Group Payout ratio
2027e	121.05 %
2026e	121.06 %
2025e	121.06 %
2024	121.05 %
2023	121.06 %
2022	121.06 %
2021	121.03 %
2020	121.1 %
2019	121.05 %
2018	120.92 %
2017	121.34 %
2016	120.88 %
2015	120.54 %
2014	122.6 %
2013	119.51 %
2012	119.51 %
2011	128.79 %
2010	110.23 %
2009	119.51 %
2008	119.51 %
2007	119.51 %
2006	119.51 %

	Payout ratio
2006	119.51 %
2007	119.51 %
2008	119.51 %
2009	119.51 %
2010	110.23 %
2011	128.79 %
2012	119.51 %
2013	119.51 %
2014	122.6 %
2015	120.54 %
2016	120.88 %
2017	121.34 %
2018	120.92 %
2019	121.05 %
2020	121.1 %
2021	121.03 %
2022	121.06 %
2023	121.06 %
2024	121.05 %
2025e	121.06 %
2026e	121.06 %
2027e	121.05 %

Date	EPS Estimate	EPS Actual	Quarterly report
6/30/2024	-0.23	-0.23 (-3.91 %)	2024 Q4
12/31/2023	-0.47	-0.51 (-8.21 %)	2024 Q2
6/30/2023	-0.58	-0.12 (78.82 %)	2023 Q4
12/31/2022	-0.93	0.15 (115.93 %)	2023 Q2
6/30/2022	-0.22	-1.48 (-566.07 %)	2022 Q4
6/30/2021	-0.51	-0.2 (60.4 %)	2021 Q4
12/31/2020	-8.08	0.42 (105.2 %)	2021 Q2
12/31/2014	0.03	0.01 (-71.72 %)	2015 Q2

%	Name	Stocks	Change	Date
7.55606 %	Viburnum Funds Pty Ltd	6,428,268	67,676	9/18/2023
6.22052 %	Mathieson (Bruce Lawrence)	5,292,066	5,183,477	9/18/2023
6.03456 %	Goldman Sachs Financial Markets Pty. Ltd.	5,133,856	4,003,980	12/12/2023
5.01268 %	Insignia Financial Ltd	4,264,499	4,264,499	10/17/2024
4.96250 %	Estetra SPRL	4,221,815	4,221,814	9/18/2023
2.66385 %	The Vanguard Group, Inc.	2,266,253	76,895	9/30/2024
1.99999 %	UBS Fund Management (Switzerland) AG	1,701,480	1,701,480	3/14/2024
1.52287 %	Gft 2 Co. Pty. Ltd.	1,295,569	-28,300	9/18/2023
1.39255 %	Vanguard Investments Australia Ltd.	1,184,699	758	9/30/2024
1.29310 %	Dimensional Fund Advisors, L.P.	1,100,096	0	8/31/2024
0.94035 %	IVL Group Pty. Ltd.	800,000	0	9/18/2023
0.88158 %	Vivnat (Curtin) Pty. Ltd.	750,000	250,000	9/18/2023
0.75323 %	DFA Australia Ltd.	640,803	-11,209	7/31/2024
0.61361 %	R & R Corbett Pty Ltd	522,028	0	9/18/2023
0.58772 %	Y S Chains Pty. Ltd.	500,000	-535,000	9/18/2023
0.56238 %	UBS Asset Management (Australia) Ltd.	478,445	44,430	3/14/2024
0.54658 %	Retzos Executive Pty. Ltd.	465,000	40,000	9/18/2023
0.48660 %	Norges Bank Investment Management (NBIM)	413,972	-142,430	6/30/2024
0.47018 %	Tzimokas (Kon)	400,000	0	9/18/2023
0.42977 %	Paltoglou (Peter)	365,626	-79,695	6/30/2023
0.41669 %	Wal Assets Pty. Ltd.	354,500	-45,500	9/18/2023
0.35263 %	Zhang (Yunsong)	300,000	300,000	9/18/2023
0.35263 %	Birbal Investments Pty. Ltd.	300,000	300,000	9/18/2023
0.34705 %	Belgravia Strategic Equities Pty. Ltd.	295,250	295,250	9/18/2023
0.29091 %	Dimensional Fund Advisors, Ltd.	247,490	0	9/30/2024
0.17799 %	Charles Schwab Investment Management, Inc.	151,427	-1,340	8/31/2024
0.11246 %	MLC Asset Management	95,675	-7	6/30/2024
0.07750 %	Condella (Frank Charles Jr)	65,929	7,154	12/1/2023
0.07153 %	O'Brien (Shawn Patrick)	60,857	23,816	9/2/2024
0.06444 %	BlackRock Investment Management (Australia) Ltd.	54,822	0	8/31/2024
0.05395 %	State Street Global Advisors (US)	45,900	-690	9/30/2024
0.04467 %	MacFarlane (Kathryn)	38,000	18,000	10/25/2023
0.04402 %	American Century Investment Management, Inc.	37,450	0	6/30/2024
0.04038 %	BetaShares Capital Ltd.	34,356	284	9/30/2024
0.03731 %	Robinson (Bruce Gregory)	31,745	0	6/30/2023
0.02597 %	Blake (Patrick J)	22,097	0	6/30/2023
0.02511 %	Custin (Ann)	21,362	12,287	10/23/2023
0.02351 %	Myers Carolyn J	20,000	0	7/31/2023
0.01316 %	MLC Investments Limited	11,192	978	5/31/2024
0.01016 %	State Street Global Advisors Australia Ltd.	8,640	-93	9/30/2024
0.00257 %	Goldman Sachs Asset Management, L.P.	2,190	0	12/12/2023
0.00122 %	Vanguard Global Advisers LLC	1,040	0	9/30/2024
0.00111 %	Mackenzie Investments	942	-4,958	6/30/2024
0.00071 %	Connor, Clark & Lunn Investment Management Ltd.	603	165	5/31/2024
0.00000 %	Goldman Sachs Asset Management B.V.	2	0	12/12/2023
0 %	RAM Active Investments S.A.	0	-4,452	6/30/2024
0 %	Heritage Wealth Advisors, LLC	0	-1,000	6/30/2024
0 %	KLP Fondsforvaltning AS	0	-9,076	10/31/2023
0 %	Geode Capital Management, L.L.C.	0	-19,079	6/30/2023
0 %	Northern Trust Global Investments Limited	0	-9,250	6/30/2023
0 %	BlackRock Asset Management Canada Limited	0	-27,554	5/31/2023
0 %	Evli Fund Management Company Ltd.	0	-1,040	4/30/2023
0 %	Pictet Asset Management Ltd.	0	-3,945	5/31/2023
0 %	BlackRock Investment Management (UK) Ltd.	0	-6,406	5/31/2023
0 %	UBS Asset Management (UK) Ltd.	0	-34,050	6/30/2023
0 %	Legal & General Investment Management Ltd.	0	-4,015	6/30/2023
0 %	AXA Investment Managers UK Ltd.	0	-59,020	4/30/2023
0 %	BlackRock Advisors (UK) Limited	0	-40,915	5/31/2023
0 %	Z¿rcher Kantonalbank (Asset Management)	0	-16,769	5/31/2023
0 %	DWS Investment GmbH	0	-9,071	6/30/2023
0 %	UBS Asset Management (Switzerland)	0	-39,604	6/30/2023
0 %	State Street Global Advisors Ireland Limited	0	-16,084	6/30/2023
0 %	BlackRock Institutional Trust Company, N.A.	0	-682,094	5/31/2023
0 %	Florida State Board of Administration	0	-21,743	12/31/2023
0 %	Nuveen LLC	0	-37,514	5/31/2023
0 %	Bessemer Trust Company, N.A. (US)	0	-13,545	7/31/2024
0 %	AllianceBernstein L.P.	0	-305	6/30/2023
0 %	California State Teachers Retirement System	0	-76,629	6/30/2023
0 %	Avantis Investors	0	-68,940	12/31/2023
0 %	Macquarie Investment Management Global Ltd.	0	-2,463	5/31/2024

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
HSBC Holdings	SupplierCustomer	0,83	-0,03	0,62	-0,27	-0,50	-0,47
Mithra Pharmaceuticals	SupplierCustomer	0,71	-0,71	-0,18	0,33	0,58	0,41
Teligent	SupplierCustomer	0,66	-0,26	-0,15	0,60
JPMorgan Chase	SupplierCustomer	0,48	-0,41	0,01	0,54	0,58	-0,29
Citigroup	SupplierCustomer	0,36	0,26	0,03	0,44	0,72	0,03
X4 Pharmaceuticals	SupplierCustomer	0,10	-0,74	-0,83	0,39	0,82	0,75
SAWAI GROUP HOLDINGS	SupplierCustomer	-0,62	-0,70	-0,39	0,22	0,58	0,70

What values and corporate philosophy does Mayne Pharma Group represent?

Mayne Pharma Group Ltd is a pharmaceutical company that values innovation, integrity, and patient care. With a commitment to developing high-quality, affordable medications, Mayne Pharma Group Ltd aims to improve the health and well-being of individuals worldwide. The company's corporate philosophy revolves around delivering effective solutions through research, development, and manufacturing of pharmaceutical products. Mayne Pharma Group Ltd prioritizes transparency, ethical practices, and collaboration in its operations, ensuring compliance with regulatory standards. By focusing on customer needs and advancing pharmaceutical technologies, Mayne Pharma Group Ltd continues to build a reputation as a trusted and forward-thinking healthcare organization.

In which countries and regions is Mayne Pharma Group primarily present?

Mayne Pharma Group Ltd primarily operates in various countries and regions around the world. The company has a strong presence in Australia, where it is headquartered, and it also has a significant presence in the United States. With a focus on developing, manufacturing, and marketing branded and generic pharmaceutical products, Mayne Pharma Group Ltd serves customers and healthcare professionals in these key markets. Additionally, the company's global reach extends to other regions, including Europe and Asia, where it actively pursues business opportunities and fosters growth. Mayne Pharma Group Ltd's international presence underscores its commitment to delivering high-quality healthcare solutions to a diverse range of patients globally.

What significant milestones has the company Mayne Pharma Group achieved?

Mayne Pharma Group Ltd has achieved significant milestones in its journey. Some notable accomplishments include the acquisition of Metrics Contract Services, a contract development and manufacturing organization. This strategic move expanded the company's capability to offer a full-service platform for pharmaceutical development and manufacturing. Mayne Pharma also received FDA approval for various generic and specialty pharmaceutical products, further strengthening its market presence in the United States. Additionally, the company successfully launched new products, such as Doryx, in the dermatology segment, and secured international distribution agreements. Mayne Pharma Group Ltd continues to strive for innovative solutions in the pharmaceutical industry to enhance shareholder value and meet patient needs.

What is the history and background of the company Mayne Pharma Group?

Mayne Pharma Group Ltd is an Australian pharmaceutical company with a rich history and background. Founded in 1845 as FH Faulding & Co, it has established itself as a reputable player in the industry. In 2015, the company acquired the generic products division of a large U.S. pharmaceutical company, strengthening its global presence. Mayne Pharma Group Ltd specializes in the development and manufacture of generic and specialty pharmaceutical products, focusing on areas such as oncology, dermatology, and women's health. With a commitment to quality and innovation, Mayne Pharma Group Ltd continues to make significant contributions to the healthcare sector globally.

Who are the main competitors of Mayne Pharma Group in the market?

The main competitors of Mayne Pharma Group Ltd in the market include companies like Teva Pharmaceutical Industries Ltd, Fagron NV, and Bio-Pharmaceutics, Inc. These companies operate in the pharmaceutical industry, focusing on generic drugs and specialty pharmaceuticals, similar to Mayne Pharma Group Ltd. By constantly monitoring and analyzing competition, Mayne Pharma Group Ltd strives to maintain its position and market share through strategic business decisions and product innovations.

In which industries is Mayne Pharma Group primarily active?

Mayne Pharma Group Ltd is primarily active in the pharmaceutical industry.

What is the business model of Mayne Pharma Group?

Mayne Pharma Group Ltd operates as a pharmaceutical company. Its business model revolves around developing, manufacturing, and distributing branded and generic prescription pharmaceuticals. Mayne Pharma specializes in providing contract development and manufacturing services to customers worldwide. By leveraging its expertise, capabilities, and global reach, Mayne Pharma aims to provide cost-effective and high-quality pharmaceutical products. The company focuses on various therapeutic areas, including cardiology, oncology, women's health, dermatology, and specialty products, catering to the needs of patients and healthcare professionals. Mayne Pharma Group Ltd strives to deliver innovative healthcare solutions and improve patient outcomes through its comprehensive business model.

What is the P/E ratio of Mayne Pharma Group 2024?

The Mayne Pharma Group P/E ratio is -2.34.

What is the P/S ratio of Mayne Pharma Group 2024?

The Mayne Pharma Group P/S ratio is 1.03.

What is the Quality Investing of Mayne Pharma Group?

The Quality Investing for Mayne Pharma Group is 3/10.

What is the revenue of Mayne Pharma Group 2024?

The Mayne Pharma Group revenue is 395.47 M AUD.

How high is the profit of Mayne Pharma Group 2024?

The Mayne Pharma Group profit is -174.23 M AUD.

What is the business model of Mayne Pharma Group

Mayne Pharma Group Ltd is an Australian pharmaceutical company headquartered in Salisbury, South Australia. It was founded in 2015 through the merger of Mayne Pharma Limited and Hospira Australia Pty Ltd. The company specializes in the development, manufacturing, and marketing of generic and specialized pharmaceutical products. Overall, the company operates in four main business segments: generics, specialized products, contract manufacturing, and distribution in the United States. Mayne Pharma's generics division produces a wide range of pharmaceutical products in various categories such as cardiology, gastroenterology, analgesics, and antibiotics. Mayne Pharma is also involved in the manufacture of generics with controlled release of active ingredients and long-acting generics. Mayne Pharma's specialized products are medicines used to treat rare or chronic diseases and often have higher added value than standard generics. This includes products in the fields of dermatology, oncology, endocrinology, urology, and psychiatry. Mayne Pharma also operates contract manufacturing, using its own infrastructure to manufacture products on behalf of third parties. Mayne Pharma's contract manufacturing offers both small and large molecule products. This option allows companies to manufacture their own products without having to build their own production and development system. In the United States, Mayne Pharma is involved in the distribution of pharmaceutical products and operates a distribution channel in the industry. This expands Mayne Pharma's portfolio with commercially attractive and acquired active ingredients and excipients. Mayne Pharma has a strong portfolio of products and assets to make it a leading provider of generic and specialized pharmaceuticals. The company also has a solid pipeline of compounds in various stages to support future growth. Mayne Pharma's success is based on a combination of high quality standards, competitive prices, a strong pipeline portfolio, and a dedicated strategic partnership with other companies in the industry. Mayne Pharma is focused on providing its customers with high quality and affordable medications and strengthening its leadership position in global markets.

What is the Mayne Pharma Group dividend?

Mayne Pharma Group pays a dividend of 0 AUD distributed over payouts per year.

How often does Mayne Pharma Group pay dividends?

The dividend cannot currently be calculated for Mayne Pharma Group or the company does not pay out a dividend.

What is the Mayne Pharma Group ISIN?

The ISIN of Mayne Pharma Group is AU000000MYX0.

What is the Mayne Pharma Group WKN?

The WKN of Mayne Pharma Group is A1C821.

What is the Mayne Pharma Group ticker?

The ticker of Mayne Pharma Group is MYX.AX.

How much dividend does Mayne Pharma Group pay?

Over the past 12 months, Mayne Pharma Group paid a dividend of 0.78 AUD . This corresponds to a dividend yield of about 15.15 %. For the coming 12 months, Mayne Pharma Group is expected to pay a dividend of -0.27 AUD.

What is the dividend yield of Mayne Pharma Group?

The current dividend yield of Mayne Pharma Group is 15.15 %.

When does Mayne Pharma Group pay dividends?

Mayne Pharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mayne Pharma Group?

Mayne Pharma Group paid dividends every year for the past 1 years.

What is the dividend of Mayne Pharma Group?

For the upcoming 12 months, dividends amounting to -0.27 AUD are expected. This corresponds to a dividend yield of -5.29 %.

In which sector is Mayne Pharma Group located?

Mayne Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mayne Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mayne Pharma Group from 1/27/2023 amounting to 0.777 AUD, you needed to have the stock in your portfolio before the ex-date on 1/18/2023.

When did Mayne Pharma Group pay the last dividend?

The last dividend was paid out on 1/27/2023.

What was the dividend of Mayne Pharma Group in the year 2023?

In the year 2023, Mayne Pharma Group distributed 0 AUD as dividends.

In which currency does Mayne Pharma Group pay out the dividend?

The dividends of Mayne Pharma Group are distributed in AUD.

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Percentage of female employees	45
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

Stock Exchange	Mayne Pharma Group Ticker
ASX	MYX.AX
DÜSSELDORF	HG6.DU
FRANKFURT	HG6.F
HAMBURG	HG6.HM
PNK	MAYNF

Mayne Pharma Group Ticker	Mayne Pharma Group FIGI
MYX:AU	BBG000BLN683
MYX:AT	BBG000BLN6N6
HG6:GR	BBG000RJ7VB0
HG6:GF	BBG000RJ7VV8
HG6:GB	BBG000RJ7WT9
MYX:AH	BBG002F3HBP2
MAYNF:US	BBG0046WCJR0
MAYNF:PQ	BBG0046WCK51
MAYNF:UV	BBG0046WCK79
MYXEUR:EO	BBG00DKHGPK6
MYXEUR:XH	BBG00DKHGPN3
MYXEUR:XF	BBG00DKHGPQ0
MYXEUR:XE	BBG00DKHGPS8
MYXEUR:XJ	BBG00DKHGPT7
MYXEUR:XL	BBG00DKHGPV4
MYXEUR:XG	BBG00DKHGPW3
MYXEUR:XO	BBG00DKHGPX2
MYXEUR:XS	BBG00DKHGQ15
MYXEUR:XA	BBG00DKHGQ24
MYXEUR:E1	BBG00DKHGQ33
MYXEUR:XT	BBG00DKHGQ42
MYXEUR:XW	BBG00DKHGQ51
MYXEUR:XU	BBG00DKHGQ60
MYXEUR:XV	BBG00DKHGQ79
MYXEUR:EU	BBG00DKHGQ97
MYXEUR:XX	BBG00JN8JLH0
MYXAUD:X2	BBG00JSC5HS8
MYXAUD:XB	BBG00JSC5HT7
MYXAUD:XH	BBG00JSC5HW3
MYXAUD:XF	BBG00JSC5HY1
MYXAUD:XE	BBG00JSC5J04
MYXAUD:XJ	BBG00JSC5J13
MYXAUD:XL	BBG00JSC5J22
MYXAUD:XG	BBG00JSC5J31
MYXAUD:XO	BBG00JSC5J40
MYXAUD:XS	BBG00JSC5J86
MYXAUD:XA	BBG00JSC5J95
MYXAUD:E1	BBG00JSC5JB2
MYXAUD:XT	BBG00JSC5JC1
MYXAUD:XW	BBG00JSC5JD0
MYXAUD:XU	BBG00JSC5JF8
MYXAUD:XV	BBG00JSC5JG7
MYXAUD:XM	BBG00JSC5JH6
MYXAUD:XQ	BBG00JSC5JK2
MYXAUD:XX	BBG00JSC5JL1
MYXAUD:XZ	BBG00JSC5JM0
MYXAUD:EU	BBG00JSC5JP7

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
0	0	0	0	36	50	52	84	143	141	267	572	530	526	457	401	157	190	395	438	480	562
-	-	-	-	-	38.89	4.00	61.54	70.24	-1.40	89.36	114.23	-7.34	-0.75	-13.12	-12.25	-60.85	21.02	107.89	10.89	9.59	17.08
-	-	-	-	47.22	46.00	44.23	46.43	52.45	56.03	63.67	56.82	53.58	60.08	46.39	45.39	47.77	47.37	56.96	51.37	46.88	40.04
0	0	0	0	17	23	23	39	75	79	170	325	284	316	212	182	75	90	225	0	0	0
0	-1	-3	-3	3	1	6	-2	21	7	37	88	-133	-279	-92	-208	-281	117	-174	-19	-4	19
-	-	200.00	-	-200.00	-66.67	500.00	-133.33	-1,150.00	-66.67	428.57	137.84	-251.14	109.77	-67.03	126.09	35.10	-141.64	-248.72	-89.08	-78.95	-575.00
29.4	62	106.8	106.8	178.7	215.1	214.6	443.3	645.6	715.45	858	73.02	73.14	73.75	76.47	78.58	82.3	82.18	79.62	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Access the world's leading financial data and tools

Price

Price

TickerMYX.AX

ISINAU000000MYX0

WKNA1C821

Mayne Pharma Group stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Mayne Pharma Group Stock Price History

Mayne Pharma Group Revenue, EBIT, Net Income AU000000MYX0 · A1C821

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Mayne Pharma Group Revenue, EBIT and net profit per share

Mayne Pharma Group Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Mayne Pharma Group stock margins AU000000MYX0 · A1C821

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Mayne Pharma Group Margin History

Mayne Pharma Group Stock Sales Revenue, EBIT, Earnings per Share AU000000MYX0 · A1C821

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Mayne Pharma Group Revenue, EBIT and net profit per share

Mayne Pharma Group business model

Mayne Pharma Group SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

The World’s Best Investors Are On Eulerpool

Mayne Pharma Group Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Mayne Pharma Group historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

Mayne Pharma Group shares outstanding AU000000MYX0 · A1C821

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Mayne Pharma Group stock splits

Mayne Pharma Group dividend history and estimates AU000000MYX0 · A1C821

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Ticker
MYX.AX

ISIN
AU000000MYX0

WKN
A1C821